Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Declines By 69.4%

Capricor Therapeutics, Inc. (NASDAQ:CAPR) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 5,029,282 shares, a decline of 69.4% from the November 30th total of 16,419,579 shares. Based on an average trading volume of 8,567,200 shares, the short-interest ratio is currently 0.6 days. Approximately 12.3% of the company’s stock are short sold. Approximately 12.3% of the company’s stock are short sold. Based on an average trading volume of 8,567,200 shares, the short-interest ratio is currently 0.6 days.

Capricor Therapeutics Trading Up 1.3%

CAPR opened at $29.29 on Thursday. The company’s 50 day moving average is $12.85 and its 200 day moving average is $9.73. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -16.27 and a beta of 0.61. Capricor Therapeutics has a 12-month low of $4.30 and a 12-month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, hitting the consensus estimate of ($0.54). As a group, analysts predict that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Capricor Therapeutics by 2.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 113,650 shares of the biotechnology company’s stock worth $1,079,000 after buying an additional 2,314 shares during the period. Deutsche Bank AG raised its stake in Capricor Therapeutics by 10.9% during the 1st quarter. Deutsche Bank AG now owns 28,699 shares of the biotechnology company’s stock worth $272,000 after acquiring an additional 2,822 shares during the period. Swiss National Bank raised its stake in Capricor Therapeutics by 17.7% during the 1st quarter. Swiss National Bank now owns 79,300 shares of the biotechnology company’s stock worth $753,000 after acquiring an additional 11,900 shares during the period. Nuveen LLC purchased a new position in Capricor Therapeutics during the first quarter valued at approximately $846,000. Finally, Wellington Management Group LLP boosted its position in shares of Capricor Therapeutics by 170.3% in the first quarter. Wellington Management Group LLP now owns 110,731 shares of the biotechnology company’s stock worth $1,051,000 after purchasing an additional 69,772 shares during the period. Institutional investors own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CAPR. Piper Sandler restated an “overweight” rating and set a $45.00 price target (up from $20.00) on shares of Capricor Therapeutics in a report on Wednesday, December 10th. HC Wainwright upped their target price on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, December 3rd. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a report on Wednesday, December 3rd. Maxim Group lifted their target price on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Finally, B. Riley reiterated a “buy” rating and set a $50.00 target price (up from $21.00) on shares of Capricor Therapeutics in a research note on Monday, December 15th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.